Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME study of Lu AF28996 in healthy men
NCT06337110Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lu AF28996 in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoints: Total Recovery of the Administered Radiolabelled Drug-related Material (Percentage of Dose in Urine and Faeces), Area Under the Plasma Concentration Curve of Radiolabelled Drug-related Material from Zero to Infinity and 7 more. Started Apr 2024; status: completed.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06337110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337110.